Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VECT
- Price
- -
- Stock movement up
- +- (%)
- Company name
- VectivBio Holding AG
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Pharmaceuticals
- Market cap
- 1.06B
- Ent value
- 876.10M
- Price/Sales
- 1565.50
- Price/Book
- 4.96
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 180.37%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
VECT does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 80.46 |
| Price to FCF | 40.34 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1565.50 |
| Price to Book | 4.96 |
| EV to Sales | 1296.00 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 62.81M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 221.42M |
| Net receivables | 1.43M |
| Total current assets | 226.21M |
| Goodwill | 923.00K |
| Intangible assets | 25.23M |
| Property, plant and equipment | 0.00 |
| Total assets | 252.60M |
| Accounts payable | 1.80M |
| Short/Current long term debt | 10.46M |
| Total current liabilities | 24.74M |
| Total liabilities | 39.23M |
| Shareholder's equity | 213.37M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| VECT | S&P500 | |
| Current price drop from All-time high | -30.46% | -4.92% |
| Highest price drop | -88.32% | -19.00% |
| Date of highest drop | 3 Dec 2021 | 8 Apr 2025 |
| Avg drop from high | -65.60% | -2.76% |
| Avg time to new high | 573 days | 5 days |
| Max time to new high | 572 days | 89 days |
COMPANY DETAILS
Marketcap
1.06B
Marketcap category
Small-cap
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner